Press release
Homozygous Familial Hypercholesterolemia Market is Forecast to Grow at a CAGR of 2.5% from 2025-2033 | AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd.
Homozygous Familial Hypercholesterolemia Market
Homozygous Familial Hypercholesterolemia Market analysis, according to DataM Intelligence, offers more than just an overview, it investigates the underlying aspects of the sector. The study provides an overview, the research explores the hidden aspects of the sector, breaking down its intricate dynamics, charting regional dominance, spotting demand patterns, and spotting prospective breakthroughs that could influence how businesses operate in the future.
Get a Free Sample PDF copy of the report - https://datamintelligence.com/download-sample/homozygous-familial-hypercholesterolemia-market
The Homozygous Familial Hypercholesterolemia market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.
Homozygous familial hypercholesterolemia (HoFH) is a rare, genetic disorder characterized by extremely high levels of low-density lipoprotein (LDL) cholesterol from birth due to mutations in both copies of cholesterol-regulating genes. It significantly increases the risk of early-onset cardiovascular diseases, requiring aggressive treatments such as lipid-lowering medications, LDL apheresis, or gene therapies.
Forecast Growth Projected:
The Global Homozygous Familial Hypercholesterolemia Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2033. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
List of the Key Players in the Homozygous Familial Hypercholesterolemia Market:
AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd., Accord Healthcare, Changzhou Pharmaceutical Factory, Regeneron Pharmaceuticals, Inc., Amryt Pharma plc, Amgen Inc., Organon, Global Inc., CMP Pharma
Segment Covered in the Homozygous Familial Hypercholesterolemia Market:
By Drug Class: Statins, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, MTP Inhibitors, ANGPTL3 Inhibitors
By Route of Administration: Oral, Parenteral, Nasal
By Technology: CRISPR-Cas9, RNA Interference, Nanoparticle-Based Therapies
By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies
Industry Development:
On March 22, 2023, Regeneron Pharmaceuticals, Inc. announced that the FDA extended the approval of Evkeeza (evinacumab-dgnb) for use in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). This makes Evkeeza the first angiopoietin-like 3 (ANGPTL3) inhibitor approved for children as young as 5, helping to lower dangerously high LDL cholesterol levels in HoFH patients when used alongside other lipid-lowering treatments.
Get this Premium Report: https://www.datamintelligence.com/buy-now-page?report=homozygous-familial-hypercholesterolemia-market
Regional Break out:
The global Homozygous Familial Hypercholesterolemia Market report focuses on six major regions: North America, South America, Europe, Asia Pacific, the Middle East, and Africa.
☞ North America - US, Canada, Mexico
☞ Europe- Germany, UK, France, Italy, Spain, Rest of Europe
☞ Asia Pacific- China, India, Japan, Australia, Rest of Asia Pacific
☞ South America- Brazil, Argentina, Rest of South America
☞ Middle East and Africa
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of Homozygous Familial Hypercholesterolemia manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of Homozygous Familial Hypercholesterolemia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/homozygous-familial-hypercholesterolemia-market
Frequently asked questions:
➠ What is the global sales value, production value, consumption value, import and export of Homozygous Familial Hypercholesterolemia market?
➠ Who are the global key manufacturers of the Homozygous Familial Hypercholesterolemia Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?
➠ What are the Homozygous Familial Hypercholesterolemia market opportunities and threats faced by the vendors in the global Homozygous Familial Hypercholesterolemia Industry?
➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?
➠ What focused approach and constraints are holding the Homozygous Familial Hypercholesterolemia market?
➠ What are the different sales, marketing, and distribution channels in the global industry?
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Homozygous Familial Hypercholesterolemia Market is Forecast to Grow at a CAGR of 2.5% from 2025-2033 | AstraZeneca, Viatris Inc., Teva Pharmaceutical Industries Ltd. here
News-ID: 3836920 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Accountable Care Solutions Market: Key Strategies for Healthcare P …
DataM Intelligence unveils its latest report on the "Accountable Care Solutions Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies…
India Fintech & UPI Market to hit US$ 12.52 Trillion by 2032 | Major Companies l …
The India fintech & UPI Payments market reached US$ 2.50 Trillion in 2024 and is expected to reach US$ 12.52 Trillion by 2032, growing at a CAGR of 22.3% during the forecast period 2025-2032.
The India Fintech & UPI Payments Market, as examined by DataM Intelligence, provides a thorough industry overview enriched with detailed insights, historical data, and essential statistics. The report extensively explores market dynamics and competitive landscapes, featuring profiles…
United States Chronic Obstructive Pulmonary Disease (COPD) Biologics Market 2025 …
Market Size and Growth
The global chronic obstructive pulmonary disease (COPD) biologics market size reached US$ 604.70 million in 2024 is expected to reach US$ 1,678.90 million by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033.
Key Development:
United States: Recent Industry Developments
✅ In July 2025, Merck announced a $10 billion acquisition of Verona Pharma, aiming to expand its cardiopulmonary portfolio and enhance access to Ohtuvayre for COPD patients.
✅…
United States Surgical Mesh Market: Emerging Products, Strategies & Competitive …
Surgical Mesh Market Size reached US$ 2.05 Billion in 2024 and is expected to reach US$ 3.62 Billion by 2033, growing at a CAGR of 6.6% during the forecast period 2025-2033.
DataM Intelligence unveils its latest report on the "Surgical Mesh Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging…
More Releases for Homozygous
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Homozygous Familial Hypercholesterolemia Market 2025 | Market Growth, Genetic Sc …
Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2030 growing with a CAGR of 2.5% during the forecast period 2023-2030, according to DataM Intelligence research report, as per DataM intelligence research report.
Homozygous Familial Hypercholesterolemia Market: Recent Industry Developments
United States
✅ Regeneron announced the FDA extension of Evkeeza use to children aged 5-11 with HoFH, making it the first ANGPTL3 inhibitor…
New Syndrome: seemingly unrelated symptoms have a common cause in patients with …
The International H63D Mutation Research Consortium www.h63d-syndrome.org has announced the discovery of "Typ-2 H63D Syndrome", a genetic disease caused by a homozygous mutation of the HFE gene H63D. The research work, which spanned 12 years, uncovered that the mutation is responsible for a wide range of symptoms due to micro-inflammations, which can be challenging to diagnose without the proper knowledge and testing.
While classic Typ-1 H63D Syndrome is a rare disorder…
Latest Homozygous Familial Hypercholesterolemia Treatment Market Research | Comp …
Homozygous Familial Hypercholesterolemia Treatment Market
Market Strides has added a new report titled, “Global Homozygous Familial Hypercholesterolemia Treatment Market Professional Report 2027” to its vast repository of research reports. This is a comprehensive report focused on the current and future prospects of the Global Homozygous Familial Hypercholesterolemia Treatment Market. The report also mentions the impact of the coronavirus pandemic on the market. Furthermore, the study includes the steps the leading industry…
Homozygous Familial Hypercholesterolemia Treatment Market Size - Technological A …
Up Market Research (UMR) has published a latest market research report on Global Homozygous Familial Hypercholesterolemia Treatment Market. The global report is prepared in collaboration with the leading industry experts and dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.
The…
